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Abstract Objective: We aimed to determine safety and feasibility of thulium laser transure-
thral vapoenucleation of prostate (ThuVEP) for treatment of obese patients affected by benign
prostatic hyperplasia (BPH).
Methods: We retrospectively analysed data of 452 patients with BPH who underwent ThuVEP
from February 2012 to March 2016 in a single center. Patients were divided into three groups
according to body mass index (BMI, kg/m2): Normal weight (18.5 ! BMI< 25; Group A), over-
weight (25 ! BMI< 30; Group B) and obese (BMI" 30; Group C), for a total of 412 patients eva-
luable for this study. Preoperative total serum prostate-specific antigen (PSA), digital rectal
examination of the prostate, transrectal ultrasound (TRUS), renal ultrasound, urine culture,
uroflowmetry, International Prostate Symptoms Score (IPSS), and Quality of Life (QoL) score
were analyzed. Post-operative complications, hospital stay and days of catheterization, ques-
tionnaires and uroflowmetry at 1 and 3 months after surgery were evaluated. Preoperative
data, surgical outcomes, complication rate and clinical outcomes were compared between
groups.
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Results: The median age of patients was 69 years (Interquartile Range [IQR 10]). The preoper-
ative median IPSS among groups was 19 (IQR 8.75), 20 (IQR 10), and 18 (IQR 10) respectively. At
1 and 3 months of follow-up, this value was 8 (IQR 7), 8 (IQR 4), 7 (IQR 5) and 5 (IQR 6.25), 5
(IQR 6), 6 (IQR 5), respectively (all p between groups> 0.05). There was no statistically signif-
icant difference among three groups as for hospital stay and days of catheterization (p > 0.05).
Conclusion: Our results showed that ThuVEP was safe and feasible even in overweight patients
with substantially enlarged prostate.
ª 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Since the last decades of the 20th century the increase of
bodyweight has progressively become a worldwide epi-
demic disorder, leading to higher incidence of morbidity
and mortality [1].
More recently in the United States, 20% of adults were
clinically obese (defined by a body mass index [BMI] of
30 kg/m2 or higher), while 30% were defined as overweight
(BMI between 25 and 30 kg/m2) [2].
Benign prostatic hyperplasia (BPH) is one of the most
common diseases in men, with an incidence that increases
with aging, observed in about 20% of men in the fourth
decade of life with a rising trend that reaches almost the
80% after 80 years of age [3,4].
Even though there are many standards to define an
excess of bodyweight, several studies reported the associ-
ation between obesity and BPH, showing the central obesity
among the top risk factors for development of prostate
enlargement. Lee et al. [5] described how an increase of
waist circumference was significantly and positively asso-
ciated with serum prostate-specific antigen (PSA), prostate
volume, and International Prostate Symptom Score (IPSS),
with a consequent worsening in voiding function.
The most established operative methods in the treatment
of prostate enlargement are the transvesical prostatectomy
and the transurethral resection of prostate (TURP).
According to EAU-Guidelines-Management-of-non-
neurogenic-male-LUTS-2016, TURP is the current surgical
standard procedure for men with prostate size of
30e80 mL, meanwhile open prostatectomy (OP) and laser
endoscopic enucleation are the gold standard in men with
enlarged prostate >80 mL.
However, it is widely described that OP is associated
with a high morbidity rate, noteworthy blood loss and
prolonged hospitalization [6].
Furthermore, some studies demonstrated an association
between obesity and metabolic syndrome with worse uri-
nary symptoms recovery after TURP or OP [7,8].
Among the minimally invasive alternatives that have been
proposed in the clinical practice field, one is the thulium laser,
a technology that uses wavelengths ranging from 1.75 mm
to 2.22 mm to vaporize or enucleate the prostate tissue.
It has been demonstrated that thulium vapoenucleation
of the prostate (ThuVEP) is effective, reliable, and
safe when employed for the treatment of prostate
enlargement [9].
However, currently published reports on thulium laser
treatment of large prostates are still rare.
The aim of our study is to assess the safety and feasi-
bility of the thulium laser treatment for prostate enlarge-
ment, assessing the perioperative and functional outcomes
stratifying the population for BMI and comparing normal
weight patients to overweighed.
2. Patients and methods
We studied 452 consecutive patients who underwent Thu-
VEP in a single Center.
Data were prospectively collected and retrospectively
analyzed. All patients referring to the Urology Department
of our centre were routinely requested to sign an informed
consent form to retrieve clinical data to be used for
research purposes. The possibility of receiving phone calls
and undergoing follow-up visits and diagnostic procedures
was included in the consent form. Men who denied their
consensus were excluded. Based on EAU guidelines, patients
who suffered from symptomatic BPH and had surgical in-
dications were enrolled from February 2012 to March 2016.
Patients with less than 3 months follow-up and less than
18.5 kg/m2 of BMI were excluded. Patients were divided into
two groups according to BMI (kg/m2): Group A normal weight
(18.5 ! BMI < 25); Group B overweight (BMI " 25), for a
total of 412 patients evaluable for this study. We then
selected a subgroup of obese patients (BMI "30, Group C)
from Group B and compared these patients to Group A.
Before surgery, patients underwent digital rectal ex-
amination of the prostate, transrectal ultrasound (TRUS) to
measure prostate and adenoma volume, renal ultrasound,
urine culture, and uroflowmetry. In addition, total PSA, IPSS
score, Quality of Life (QoL) score were evaluated. Patients
with PSA level >4 ng/mL underwent TRUS biopsy to exclude
prostate carcinoma.
Patients were evaluated with questionnaires and uro-
flowmetry preoperatively and at one and three months
after surgery. Urinary outcomes (IPSS score, QoL, and Qmax)
were compared among the three groups of patients.
2.1. Surgical technique
All surgical procedures were performed by the same surgical
team (three surgeons) who was fully trained in ThuVEP. Sur-
geries were performed by using the Cyber TM 150 or 200
(Quanta System Cyber TM, Samarate, Italy). With the patient
in the lithotomy position, a laser resectosope with an 800 mm
end firing fiber was introduced into the urethra using saline
solution as an irrigant. Ureteral orifices and urinary sphincter
were identified and marked using a very low-power setting
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(40 W). An inverted “U” mark was performed proximal to the
verumontanum, which was used for orientation (power
setting, 40 W). Subsequently, an incision was made down to
the capsule fibers at the 05:00 and 07:00 positions from the
bladder neck to the inverted “U” mark. Then, complete
vaporesection of the middle lobe up to the abovementioned
mark was performed (power setting, 150 W), followed by
vapoenucleation of the lateral lobes down to the capsule and
on the ventral side to the level of the verumontanum (power
setting, 150W). Then, prior to retrograde vapoenucleation of
the lobes (power setting, 150W), circular vapoenucleation of
the internal bladder neck was performed by means of apical
vapoenucleation (power setting, 150 W), employing the
verumontanum as a distal border. After introduction of a
nephroscope and maintaining bladder distension, prostate
lobes weremorcellated using the Piranha (Wolf), followed by
a final check to confirm absence of obstruction or hemor-
rhage. Finally, a temporary indwelling catheter was placed
(Dufour 20 Ch) with temporary bladder irrigation.
2.2. Statistical analysis
Non normally distributed data were reported as median and
interquartile range (IQR), while categorical data were re-
ported as absolute values or percentages. Continuous data
were analyzed by using the ManneWhitney U test. Cate-
gorical data were analyzed by using the Chi-square test.
SPSS software (IBM! SPSS Statistics!v.21, IBM Corp,
Armonk, NY, USA) was used for all statistical analyses, with
p values of <0.05 considered as statistically significant.
3. Results
The study took place from February 2012 to March 2016,
and 412 consecutive patients who underwent ThuVEP were
analyzed. Results are reported in Table 1.
Comparison between the Group A and the Group B þ C
showed no statistically significant differences in ana-
graphical characteristics (age, p Z 0.853). The American
Society of Anesthesiologist (ASA) score, the presence of
diabetes and the use of anticoagulant or antiplatelet
therapy were analyzed to evaluate comorbidities. No sta-
tistically significant difference was found between Group A
and Group C (all p > 0.05).
Preoperative data reviewed regarding prostate charac-
teristics were PSA level, prostate volume, presence of a
blocker therapy and indwelling catheter. None of these
showed significant difference in the two groups except for
the prostate volume, which resulted higher in the over-
weight patients (median 75 mL vs. 60 mL, p < 0.001).
Similar considerations resulted from comparison between
the normalweight and the obese group. The only significantly
different parameter was the prostate volume, resulting
higher in the obese patients (78.5mL vs. 60.0 mL, p< 0.003).
Perioperative characteristics analyzed were operative
time, haemoglobin drop, bladder irrigation time, cathe-
terization time, and length of hospital stay. No difference
was found between Group A and Group B þ C with regards
to all these parameters (Table 1).
Comparison of normal weight patients with obese pa-
tients leads to similar results, except for the haemoglobin
decrease in the obese group, which was significantly lower
(median 0.8 vs. 1.0 mg/mL, p Z 0.031).
Functional data were assessed preoperatively, at 1 and 3
months postoperative, with the IPSS, QoL score and uro-
flowmetry (Table 1). A statistically significant difference
was found at 1 month after surgery for PVR with lower
values (Group A vs. Group B þ C, p Z 0.03). Another sta-
tistically significant difference was reported in terms of
QoL: Group A had a better improvement compared to Group
C (p Z 0.028). However these differences were no more
observed at 3 months follow-up. None of our patients re-
ported temporary urge incontinence.
Complications are reported in the Table 1 with no dif-
ferences between all groups (all p > 0.05).
4. Discussion
To our knowledge this is the first study in literature
reporting the use of thulium laser for BPH surgery in over-
weight patients. Furthermore, there is a lack of papers also
regarding the outcomes of obese patients treated with
other surgical approaches for BPH.
Thulium laser technique has been introduced as a size-
independent, minimally invasive treatment of benign
prostatic obstruction [10, 11].
In EAU guidelines, thulium laser transurethral vapoenu-
cleation or vaporization of the prostate is an alternative to
transurethral resection of the prostate (TURP) for small-
and medium-sized prostates (LE 1b GR A), and ThuLEP can
be offered as an alternative to TURP, to holmium laser
enucleation of the prostate, and open simple prostatec-
tomy for large prostates (LE 1b, 2b GR B).
Our results confirmThuVEPas effective, reliable, and safe
both in normal and overweight patients. Therefore, no sig-
nificant differences were found in terms of operative time.
As described in literature [5], our results confirmed a
positive correlation between an increased BMI and prostate
volume, a slight arise of serum PSA and a major use of
alpha-blockers, meanwhile no differences have been re-
ported in IPSS, QoL and need of catheterization due to
acute urinary retention.
Moreover, comparing the groups no discrepancies have
been reported in preoperative uroflowmetry parameters
confirming that the BPH urinary symptoms are correlated
not only with prostate volume growth, but it could be
described as multifactor pathology.
Haemoglobin decreased surprisingly lesser in Group C
than Group A, even considering the slight higher, but clin-
ically significant, rate of acetylsalicylic acid assumption in
overweight and obese patients. Comparing postoperative
results between Group A and B þ C, and Group A and C
alone, no differences have been reported in catheteriza-
tion days and hospitalization length. Furthermore, compli-
cation rate and grade were similar between Group A and
B þ C and between Group A and Group C alone.
Asmentionedbefore, it has been reported that therewas a
correlation between obesity and metabolic syndrome, and
worse urinary symptoms recovery after prostatic surgery [12].
Sener et al. [8] demonstrated a worse LUTS relief after TURP
in patients with metabolic syndrome. A study conducted by
Gacci et al. [7] reported incomplete recovery of total IPSS and
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storage IPSS in patients with waist circumference > 102 cm
after OP and TURP. Also Cui et al. [13]. have recently shown a
not-negligible rate of transitory urge incontinence (19% vs.
23%) and dysuria (28% vs. 16%) after holmium laser enucle-
ation of the prostate (HoLEP) and OP, respectively. These
results were not observed in our study: Post operative IPSS
and Qmax at 1 and 3 months were significantly improved both
in normal and overweight patients suggesting that thulium
approach can offer better functional post-operative results
irrespectively of patients’ weight than TURP, HoLEP or OP.
Table 1 Patients characteristics, preoperative functional characteristics, perioperative data, 1 and 3 months follow-up
functional data, and postoperative complications.
Parameters Group A
18.5 kg/m2! BMI < 25 kg/m2
n Z 177
Group B þ C
BMI " 25 kg/m2
n Z 235
Group C






Age, year; mean (SD)/median (IQR) 70 (11) 69 (10) 68 (8.5) 0.853 0.804
PSA, ng/mL; mean (SD)/median (IQR) 2.50 (2.96) 2.91 (3.7) 3.34 (3) 0.241 0.163
Prostate volume, mL; mean (SD)/median (IQR) 60 (47.65) 75 (52) 78.5 (45) <0.001 0.003
Indwelling catheter, n (%)
Yes 47 (25.4) 51 (21.7) 8 (14.8)
No 130 (74.6) 184 (78.3) 46 (85.2) 0.232 0.077
Diabetes, n (%)
Yes 17 (9.6) 33 (14.0) 10 (19)
No 125 (70.6) 148 (63) 34 (62)
Unknown 35 (19.8) 54 (23) 10 (19) 0.157 0.078
Alpha blocker, n (%)
Yes 116 (65.5) 167 (71) 39 (72.2)
No 61 (34.5) 68 (29) 15 (27.8) 0.253 0.361
Antiplatelet or anticoagulant medications, n (%)
Acetylsalicylic acid 37 (21) 60 (25.5) 15 (27.8) 0.310 0.290
Other antiplatelet drugs 9 (5.0) 8 (3.4) 1 (1.8) 0.537 0.307
Anticoagulant drugs 13 (7.4) 14 (6) 4 (7.4) 0.905 0.988
No 118 (66.6) 153 (65.1) 34 (63.0) 0.163 0.051
ASA score, n (%)
1 31 (17.5) 38 (16.1) 6 (11.1) 0.837 0.261
2 110 (62.7) 154 (65.6) 35 (64.8) 0.495 0.597
3 36 (19.8) 43 (18.3) 13 (24.1) 0.280 0.495
4 0 0 0 0 1
IPSS preop, median (IQR) 19 (8.75) 20 (10) 18 (10) 0.236 0.603
QoL score preop, median (IQR) 4 (2) 4 (2) 4 (2) 0.206 0.681
Qmax, mL/s preop; median (IQR) 8.4 (4.6) 8.0 (3.9) 8.5 (3.6) 0.702 0.913
PVR, mL preop; median (IQR) 122 (145) 120 (152.5) 109 (160) 0.743 0.968
Operative time (min); median (IQR) 70 (40) 75 (40) 85 (50) 0.096 0.066
Hb decrease (g/dL); median (IQR) 1 (1.28) 1 (1.2) 0.8 (1.15) 0.600 0.031
Bladder irrigation time (h); median (IQR) 20 (6) 20 (6) 20 (6) 0.684 0.758
Catheterization time (h); median (IQR) 34 (20) 28 (22) 28 (19.5) 0.710 0.951
Hospital stay (day); median (IQR) 2 (1) 2 (1) 2 (1) 0.902 0.732
1 month IPSS, median (IQR) 8 (7) 8 (4) 7 (5) 0.356 0.161
1 month QoL score, median (IQR) 2 (2) 2 (2) 1 (2) 0.170 0.028
1 month Qmax, mL/s; median (IQR) 16.6 (9.35) 16.1 (10.3) 18 (11.78) 0.880 0.262
1 month PVR (mL); median (IQR) 30 (39) 40 (86) 25 (83.5) 0.030 0.570
3 month IPSS, median (IQR) 5 (6.25) 5 (6) 6 (5) 0.765 0.475
3 month QoL score, median (IQR) 1 (2) 1 (2) 1 (2) 0.839 0.830
3 month Qmax, mL/s; median (IQR) 21 (9.48) 20 (9.78) 21.35 (10.8) 0.727 0.380
3 month PVR, mL; median (IQR) 15 (28.5) 0 (51) 15 (76) 0.869 0.380
AUR with recatheterization (Clavien II), n 18 29 7 0.709 0.650
Delayed morcellation (Clavien IIIa), n 1 1 0 0.840 0.580
Transfusion rate, n 4 1 0 0.169 0.575
UTI (Clavien II), n 0 2 1 0.131 0.070
MI/stroke (Clavien IV), n 1 1 0 0.840 0.580
Bladder injury (Clavien I), n 1 0 0 0.249 0.580
ASA, American Society of Anesthesiologists; IPSS, International Prostatic Symptoms Score; IQR, interquartile range; QoL, quality of life;
Qmax, maximum flow; PVR, post-void residual volume; AUR, acute urinary retention; UTI, urinary tract infection; MI, myocardial
infarction.
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The present study is subject to limitations. Firstly, it is a
single center, nonrandomized study, with a limited number
of patients forming Group C. However, the prospective
collection of data, the standardization of the ThuVEP
technique along with the detailed statistical analysis may
compensate its main limits. Secondly, the study lacks of a
long-term follow-up, however a statistically significant
improvement in the analysed functional parameters was
already observed. Finally, the majority of patients have not
undergone a urodynamic examination, because, as shown in
the literature, impaired detrusor contractility is not a
contraindication to surgery [14].
In our opinion a longer-term follow-up is needed to
evaluate the durability and possible morbidity for ThuVEP
in overweight patients.
5. Conclusion
Compared with normal weight population, overweight and
obese patients did not show a statistically significant dif-
ference about complication rate and clinical outcomes. Our
results described ThuVEP as a safe and feasible treatment
option even in obese and overweight patients and sub-
stantially enlarged prostate.
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